present
forti
antivir
drug
formal
licens
clinic
treatment
viral
infect
mainli
use
treatment
infect
caus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
herpesvirus
herp
simplex
viru
hsv
varicellazost
viru
vzv
multifoc
leukoencephalopathi
pml
hemorrhag
cystiti
patient
aid
howev
anecdot
case
report
point
efficaci
cidofovir
cytosin
hpmpc
licens
trademark
name
intraven
treatment
cmv
retin
aid
patient
treatment
polyoma
jc
bk
viru
infect
particularli
pml
aid
patient
vitro
activ
variou
acycl
nucleosid
phosphon
among
hpmpc
cidofovir
murin
primat
polyomavirus
well
establish
esterif
cidofovir
cdv
hexadecyloxypropyl
hdp
octadecyloxyethyl
ode
group
hdpcdv
odecdv
respect
result
decreas
effect
concentr
ec
increas
select
index
polyomavirus
antivir
licens
treatment
human
papillomaviru
hpv
associ
diseas
includ
wart
verruca
vulgari
condyloma
acuminatum
papillomatosi
ie
recurr
respiratori
papillomatosi
cervic
vulvar
penil
peri
anal
dysplasia
evolv
carcinoma
variou
strategi
includ
surgeri
destruct
therapi
antiprolif
agent
immunotherapi
use
treatment
hpvassoci
lesion
cidofovir
use
label
success
topic
occasion
system
treatment
hpvassoci
papillomat
lesion
mani
instanc
virtual
complet
durabl
resolut
lesion
achiev
follow
topic
applic
cidofovir
gel
cream
addit
cidofovir
acycl
nucleosid
phosphon
cprpmedap
n
explor
potenti
treatment
hpvassoci
papilloma
dysplasia
compound
shown
specif
induc
apoptosi
hpvinfect
cell
turn
may
relat
abil
restor
function
tumor
suppressor
protein
prb
neutral
oncoprotein
respect
hpvinfect
cell
recent
biphenylsulfonacet
acid
deriv
describ
inhibitor
hpv
helicaseassoci
atp
hydrolysi
although
novel
atpas
inhibitor
hardli
consid
good
drug
candid
may
serv
lead
optim
potenti
antivir
agent
activ
multipl
hpv
type
mani
viru
infect
see
supra
rna
interfer
rnai
base
small
interf
rna
advoc
block
hpv
infect
oncogen
express
sirna
approach
could
particularli
use
silenc
hpv
oncogen
cervic
intraepitheli
neoplasia
treatment
adenoviru
infect
could
quit
sever
immunocompromis
patient
ie
allogen
hematopoiet
stemcel
transplant
recipi
antivir
drug
offici
approv
anecdot
report
point
efficaci
cidofovir
adenoviru
infect
patient
among
novel
compound
could
explor
treatment
adenoviru
infect
propoxi
pyrimidin
hpmpodapi
akin
older
compound
like
adenin
hpmpa
acycl
nucleosid
purin
dideoxynucleosid
zalcitabin
ddc
alovudin
fddt
flt
found
inhibit
adenoviru
replic
vitro
fact
ddc
also
found
effect
vivo
mous
model
adenoviru
pneumonia
also
ether
lipidest
hexadecyloxypropyl
hdp
octadecyloxyethyli
ode
prodrug
hpmpc
hpmpai
design
inhibit
adenoviru
replic
vitro
significantli
lower
concentr
parent
compound
treatment
vzv
number
compound
approv
acyclovir
oral
prodrug
valaciclovir
penciclovir
oral
prodrug
famciclovir
idoxuridin
trifluridin
brivudin
penciclovir
idoxuridin
trifluridin
use
topic
primarili
treatment
herp
labiali
penciclovir
herpet
kerat
idoxuridin
trifluridin
acyclovir
use
oral
intraven
topic
wherea
valaciclovir
famciclovir
administ
oral
treatment
hsv
vzv
infect
brivudin
avail
european
countri
use
oral
treatment
herp
zoster
also
effect
infect
acyclovir
oral
prodrug
valaciclovir
remain
gold
standard
treatment
hsv
vzv
infect
attempt
made
bring
antihsv
antivzv
agent
clinic
except
prodrug
sinc
quit
number
year
still
clinic
develop
treatment
herp
zoster
acyclovir
acv
ganciclovir
gcv
tricycl
deriv
ie
tricycl
acyclovir
tacv
deriv
thereof
similar
slightli
decreas
antivir
potenc
increas
lipophil
compar
parent
compound
acv
gcv
addit
show
interest
fluoresc
properti
worth
consid
clinic
develop
antihsv
antivzv
agent
number
carbocycl
guanosin
analogu
cyclohexenylguanin
methylen
cyclopropan
synguanol
compound
owe
select
antivir
activ
specif
phosphoryl
hsvor
vzvencod
thymidin
kinas
tk
upon
phosphoryl
triphosph
form
act
chain
termin
dna
polymer
reaction
rare
circumst
hsv
vzv
becom
resist
acycl
carbocycl
guanosin
analogu
due
tk
defici
tk
pyrophosph
analogu
foscarnet
could
use
treat
tk
hsv
tk
vzv
infect
immunocompromis
patient
recent
second
gener
methylen
cyclopropan
analogu
deriv
synthes
compound
may
potenti
treatment
vzv
also
cmv
herp
ebv
infect
particular
cyclopropavir
report
effect
reduc
mortal
mice
infect
murin
cmv
recent
synthes
seri
hydroxymethyl
cyclopropyliden
methyl
adenin
guanin
z
tran
cyclopropyliden
methyl
adenin
quot
effect
ebv
ec
new
antihsv
agent
target
viral
helicaseprimas
complex
thiazolylphenyl
deriv
bil
bs
bay
recent
report
vivo
efficaci
anim
model
infect
compound
seem
function
diminish
affin
helicaseprimas
complex
hsv
dna
heterotrimer
helicaseprimas
complex
compos
gene
product
dna
helicas
dnadepend
atpas
dna
primas
activ
resist
aminothiazolylphenylbas
inhibitor
shown
aris
singl
amino
acid
chang
protein
antivir
potenc
bay
report
superior
compound
current
use
treat
hsv
infect
recent
studi
bay
shown
efficaci
famciclovir
therapi
infect
balbc
mice
also
bil
structur
relat
bil
bs
exhibit
excel
efficaci
oral
treatment
acyclovirresist
acv
r
infect
nude
mice
highlight
potenti
class
antiherpet
agent
treatment
acv
r
hsv
diseas
human
rna
interfer
rnai
gener
small
interf
rna
sirna
recent
pursu
power
tool
silenc
diseas
includ
viral
infect
pallis
et
al
shown
vagin
instil
sirna
target
gene
encod
envelop
glycoprotein
dna
bind
protein
respect
protect
mice
lethal
infect
sirna
mix
lipid
ensur
uptak
cell
vagina
ectocervix
studi
conclud
sirna
may
attract
candid
applic
microbicid
prevent
viral
infect
new
class
antivzv
compound
bicycl
furo
pyrimidin
nucleosid
analogu
bcna
repres
cf
cf
compound
exquisit
activ
vzv
inhibit
replic
vzv
virus
includ
hsv
subnanomolar
concentr
select
index
excess
given
extrem
high
potenc
select
bcna
warrant
develop
toward
clinic
use
ie
herp
zoster
five
compound
licens
treat
cmv
infect
ganciclovir
oral
prodrug
valganciclovir
foscarnet
cidofovir
fomivirsen
foscarnet
also
proven
efficaci
treatment
dna
viru
ie
hepat
b
infect
except
fomivirsen
antisens
oligonucleotid
target
cmv
immediateearli
mrna
licens
anticmv
drug
target
viral
dna
polymeras
ganciclovir
must
first
phosphoryl
cmvencod
protein
kinas
gene
product
also
princip
site
mutat
engend
resist
toward
compound
toxic
side
effect
ie
bonemarrow
suppress
ganciclovir
nephrotox
foscarnet
cidofovir
prompt
search
new
inhibitor
cmv
sever
benzimidazol
ribonucleosid
among
maribavir
previous
also
known
accredit
specif
activ
human
cmv
maribavir
seem
target
protein
kinas
gene
product
shown
account
releas
cmv
nucleocapsid
nucleu
maribavir
may
assum
target
stage
viral
life
cycl
follow
viral
dna
matur
packag
preclin
pharmacokinet
toxicolog
studi
shown
maribavir
favor
safeti
profil
excel
oral
bioavail
phase
iii
doseescal
trial
hivinfect
men
asymptomat
cmv
shed
indic
maribavir
rapidli
absorb
follow
oral
dose
reduc
cmv
titer
semen
maribavir
current
prophylaxi
studi
allogen
stem
cell
transplant
recipi
result
expect
divulg
viropharma
inc
accord
biron
biron
also
mention
two
compound
ie
bay
enter
clinic
develop
develop
despit
favor
safeti
profil
bay
shelv
favor
advanc
maribavir
maribavir
primarili
activ
cmv
potent
select
vitro
activ
three
human
cmv
compar
ganciclovir
foscarnet
higher
antivir
potenc
lower
cytotox
target
earli
stage
viral
replic
cycl
follow
viral
entri
preced
viral
dna
replic
regul
cellular
process
may
involv
protein
tyrosin
kinas
activ
cellular
kinas
inhibitor
found
enhanc
antivir
activ
maribavir
may
use
therefor
explor
possibl
therapeut
use
combin
maribavir
cellular
kinas
inhibitor
combin
maribavir
ganciclovir
recommend
sinc
maribavir
antagon
antivir
action
ganciclovir
alkoxyalkyl
ester
cidofovir
ie
hdpcdv
develop
retain
efficaci
parent
compound
without
associ
renal
toxic
significantli
improv
oral
bioavail
hdpcdv
current
develop
oral
drug
treatment
poxviru
infect
well
cmv
herpesviru
infect
present
standard
antivir
treatment
infect
also
potenti
clinic
indic
remain
illdefin
compar
studi
foscarnet
cidofovir
emerg
potent
compound
highest
antivir
select
latter
three
also
prove
potent
addit
cidofovir
hpmpa
analogu
also
identifi
potent
select
inhibitor
replic
howev
promis
activ
demonstr
compound
shown
previous
highli
effect
vitro
cmv
compound
exhibit
potenc
ec
select
si
far
exceed
standard
antiherpesviru
agent
acyclovir
ganciclovir
foscarnet
cidofovir
vitro
antivir
actionprofil
deserv
explor
vivo
potenti
treatment
cmv
infect
although
number
aforement
approv
antiherpet
drug
acyclovir
ganciclovir
brivudin
cidofovir
proven
effect
vitro
replic
ebv
none
antivir
drug
formal
approv
treatment
diseas
associ
ebv
ie
mononucleosi
infectiosa
bcell
lymphoma
lymphoprolif
syndrom
burkitt
lymphoma
nasopharyng
carcinoma
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
would
seem
appeal
examin
establish
antiherpet
drug
cidofovir
acycl
nucleosid
phosphon
hpmpa
prodrug
thereof
potenti
therapi
ebvand
malign
also
new
nucleosid
analogu
conform
lock
nucleosid
analogu
northmethanocarbathymidin
n
mct
previous
shown
block
replic
explor
potenti
prevent
treatment
malign
casu
n
mct
specif
triphosphoryl
cell
undergo
lytic
replic
effici
block
dna
replic
cell
fact
antivir
activ
spectrum
n
mct
includ
herpesvirus
ebv
thiosemicarbazen
ie
marboran
methisazon
investig
efficaci
orthopoxvirus
lengthi
histori
prophylact
therapeut
potenti
efficaci
mycobacterium
tuberculosi
howev
becom
recent
clear
class
compound
littl
potenti
orthopoxviru
infect
ie
cowpox
viru
surrog
viru
variola
viru
sever
nucleosid
analogu
ie
idoxuridin
nucleotid
analogu
ie
cidofovir
hpmpodapi
proven
effect
variou
anim
model
poxviru
infect
particular
cidofovir
shown
high
efficaci
even
administr
singl
system
intraperiton
intranas
aerosol
dose
protect
mice
lethal
respiratori
infect
either
vaccinia
cowpox
cidofovir
demonstr
high
effect
treatment
dissemin
progress
vaccinia
athymicnud
mice
human
cidofovir
use
success
topic
intraven
rout
treatment
orf
recalcitr
molluscum
contagiosum
immunocompromis
patient
cidofovir
hpmpc
congen
hpmpdap
hpmpodapi
highli
effect
orf
human
ovin
cell
monolay
organotyp
ovin
raft
cultur
given
vitro
activ
cidofovir
variola
smallpox
poxvirus
vivo
efficaci
cidofovir
variou
poxviru
infect
anim
model
human
reason
assum
cidofovir
effect
therapi
andor
prophylaxi
smallpox
case
inadvert
outbreak
biolog
attack
variola
viru
phosphon
analogu
cidofovir
limit
oral
bioavail
case
outbreak
smallpox
would
use
oral
activ
drug
hand
end
hexadecyloxypropylcidofovir
hdpcdv
octadecyloxyethylcidofovir
odecdv
design
potenti
oral
prodrug
cidofovir
alkyloxyalkyl
ester
cidofovir
found
significantli
enhanc
inhibit
replic
orthopoxvirus
ie
vaccinia
cowpox
vitro
hdpcdv
odecdv
given
oral
effect
cidofovir
given
parenter
treatment
vaccinia
cowpox
infect
hdpcdv
proven
effect
treatment
lethal
vaccinia
viru
respiratori
infect
mice
furthermor
hdpcdv
odecdv
given
oral
prove
highli
efficaci
lethal
aerosol
mousepox
ectromelia
viru
model
attest
potenti
use
alkyloxyalkyl
ester
cidofovir
oral
therapi
prophylaxi
poxviru
infect
potenti
use
recent
extend
alkoxyalkyl
ester
adenin
hpmpa
treatment
orthopoxviru
ie
vaccinia
cowpox
well
cytomegaloviru
infect
fact
indic
recent
find
cidofovir
mice
infect
ectromelia
mousepox
viru
encod
monkey
infect
monkeypox
cidofovir
cdv
hdpcdv
andor
odecdv
still
provid
best
current
hope
effect
control
virul
poxviru
infect
mutat
polymeras
gene
ie
vaccinia
viru
associ
cidofovir
resist
cidofovir
resist
associ
diminish
virul
reduc
fit
vivo
mice
cidofovir
cdv
still
protect
mice
cdvresist
vaccinia
viru
addit
nucleotid
analogu
cidofovir
primarili
act
viral
dna
chain
termin
vaccinia
viru
dna
polymeras
incorpor
penultim
posit
antivir
strategi
poxviru
infect
may
also
base
inhibitor
cellular
process
ie
signal
transduct
pathway
respect
erbb
tyrosin
kinas
inhibitor
found
block
variola
viru
replic
vitro
vaccinia
viru
infect
vivo
likewis
imatimib
ablfamili
kinas
inhibitor
use
treat
chronic
myelogen
leukemia
human
shown
suppress
poxvir
dissemin
vivo
sever
order
magnitud
promot
surviv
infect
mice
suggest
possibl
use
drug
treat
smallpox
complic
associ
vaccin
smallpox
drug
target
host
rather
viral
molecul
less
like
engend
resist
compar
specif
antivir
agent
collect
inhibitor
hostsign
pathway
exploit
poxvir
pathogen
may
repres
potenti
antivir
therapi
recent
new
antipoxviru
compound
describ
oral
bioavail
act
accord
novel
mechan
action
target
specif
viral
product
ie
vaccinia
viru
requir
extracellular
viru
particl
format
protect
mice
lethal
orthopoxviru
challeng
properti
make
attract
candid
develop
smallpox
antivir
drug
could
stockpil
use
treatment
prevent
smallpox
viru
infect
event
bioterrorist
threat
alreadi
mention
wealth
nucleosid
analogu
ie
deoxyuridin
relat
idoxuridin
neplanocin
analogu
describ
potent
inhibitor
vaccinia
viru
paradigm
poxvirus
sever
new
congen
recent
ad
list
ie
dimethoxymethyl
deoxynucleosid
chimera
cyclopentenyl
demonstr
mani
virus
smallinterf
si
rna
also
prove
effect
vaccinia
viru
ie
sirna
target
doublestrand
ds
rna
bind
protein
estim
million
peopl
worldwid
chronic
infect
hepadnaviru
hbv
approxim
million
die
year
complic
infect
includ
cirrhosi
hepatocellular
carcinoma
endstag
liver
diseas
formal
approv
treatment
chronic
hepat
b
lamivudin
adefovir
dipivoxil
pegyl
entecavir
wherea
lamivudin
adefovir
entecavir
nucleosid
analogu
still
pre
clinic
develop
act
genuin
antivir
agent
hbvassoci
revers
transcriptas
interferon
chronic
hepat
b
set
primarili
act
immunomodul
pegyl
effect
treatment
hbeagposit
chronic
hepat
b
addit
benefit
achiev
combin
lamivudin
addit
ribavirin
seem
increas
efficaci
interferon
treatment
hbeagposit
chronic
hepat
b
combin
pegyl
interferon
adefovir
dipivoxil
howev
led
mark
decreas
serum
hbv
dna
intrahepat
coval
close
circular
dna
cccdna
significantli
correl
hbsag
reduct
patient
chronic
hepat
b
wherea
interferon
therapi
also
unavoid
side
effect
influenzalik
symptom
recommend
durat
longer
year
nucleo
ide
analogu
principl
administ
quit
number
year
lamivudin
howev
prolong
treatment
compound
emerg
virolog
clinic
resist
accumul
rate
approxim
percent
patient
per
year
year
treatment
resist
primarili
due
emerg
rt
iv
mutat
ymdd
motif
hbv
dna
polymeras
although
recent
demonstr
lamivudineresist
mutat
also
emerg
outsid
ymdd
motif
resist
adefovir
dipivoxil
may
also
emerg
less
frequent
percent
year
although
may
rise
percent
year
patient
year
therapi
cite
osborn
lok
adefovir
dipivoxil
oral
prodrug
adefovir
pmea
adenin
intracellular
convers
diphosph
form
act
competit
inhibitor
altern
substrat
hbv
revers
transcriptas
incorpor
dna
act
chain
termin
therebi
prevent
dna
chain
elong
patient
chronic
hbv
infect
either
posit
neg
hepat
b
eantigen
week
treatment
dose
adefovir
dipivoxil
low
mg
per
day
result
signific
improv
paramet
diseas
histolog
liver
abnorm
serum
hbv
dna
titer
serum
alanin
aminotransferas
level
patient
hbeagneg
chronic
hepat
b
benefit
achiev
week
adefovir
dipivoxil
lost
treatment
discontinu
maintain
treatment
continu
week
adefovir
dipivoxil
mg
daili
treatment
week
prove
safe
effect
chines
subject
hbeagposit
chronic
hepat
b
period
lead
emerg
drug
resist
resist
adefovir
dipivoxil
associ
rt
rt
mutat
demonstr
sampl
patient
chronic
hbv
infect
emerg
rt
rt
mutat
common
lamivudineresist
patient
patient
adefovir
resist
associ
viral
rebound
hepat
flare
hepat
decompens
suggest
combin
lamivudin
adefovir
dipivoxil
even
patient
lamivudineresist
hbv
prevent
emerg
adefovir
resist
fact
adefovir
dipivoxil
ad
ie
hbeagneg
patient
lamivudin
soon
genotyp
resist
lamivudin
develop
entecavir
one
recent
antivir
drug
launch
clinic
use
vitro
vivo
potenc
seem
greater
lamivudin
patient
chronic
hepat
b
infect
proven
efficaci
dose
low
mg
per
day
activ
triphosph
metabolit
entecavir
would
accumul
intracellularli
concentr
inhibitori
hbv
dna
polymeras
clear
howev
translat
clinic
efficaci
entecavir
lamivudineresist
hbv
infect
earli
studi
entecavir
indic
low
resist
potenti
resist
develop
time
must
await
result
ongo
clinic
trial
comprehens
studi
entecavir
carri
patient
either
hbeagposit
chronic
hepat
b
hbeagneg
chronic
hepat
b
point
rate
histolog
improv
virolog
respons
normal
alanin
aminotransferas
level
significantli
higher
week
treatment
entacavir
lamivudin
case
resist
detect
two
year
entecavir
therapi
patient
previous
treat
lamivudin
howev
patient
fail
lamivudin
therapi
develop
entecavir
resist
two
year
therapi
number
lnucleosid
ie
ldt
telbivudin
valin
ester
deoxycytidin
valldc
valtorcitabin
uracil
lfmau
clevudin
clinic
develop
treatment
chronic
hepat
b
see
hu
et
al
far
role
deoxythymidyl
dtmp
kinas
metabol
clevudin
concern
clevudin
show
potent
antivir
activ
sustain
month
treatment
period
hbeagposit
chronic
hepat
b
patient
telbivudin
show
drug
interact
lamivudin
adefovir
dipivoxil
would
allow
combin
telbivudin
drug
pharmacokinet
viewpoint
compound
preclin
develop
includ
fluoroguanosin
flg
racivir
compound
also
activ
hiv
see
part
ii
flg
prove
equal
effect
wildtyp
lamivudineresist
andor
adefovirresist
hbv
mutant
new
class
chemic
repres
helioxanthin
recent
describ
compound
would
inhibit
hbv
replic
mechan
action
differ
antihbv
agent
describ
far
moreov
tenofovir
disoproxil
fumar
tdf
emtricitabin
ftc
counterpart
lamivudin
licens
individu
combin
treatment
hiv
infect
aid
may
also
consid
pursu
individu
combin
use
treatment
chronic
hepat
b
tdf
consid
import
new
therapeut
tool
induct
complet
remiss
patient
wit
lamivudineresist
hbv
infect
may
highli
effect
rescu
drug
hbvinfect
patient
diminish
respons
treatment
lamivudin
adefovir
dipivoxil
dose
use
treatment
hiv
infect
mgday
tdf
found
effect
wildtyp
lamivudineresist
hbv
strain
hbvhivcoinfect
patient
like
tdf
emtricitabin
ftc
activ
hiv
hbv
therefor
consid
use
patient
coinfect
hiv
hbv
interest
recommend
propos
care
patient
chronic
hbv
hiv
coinfect
put
combin
tdf
ftc
would
cover
hbv
hiv
infect
antiretrovir
therapi
would
use
patient
adefovir
dipivoxil
andor
pegyl
interferon
may
instal
depend
whether
hbeagneg
posit
respect
shown
mani
virus
rna
interfer
rnai
approach
base
short
interf
rna
sirna
also
appli
specif
inhibit
hbv
replic
vitro
cell
cultur
vivo
mice
transfect
hbv
plasmid
fact
sever
studi
demonstr
sirna
capabl
specif
inhibit
hbv
replic
vivo
thu
may
constitut
new
therapeut
strategi
hbv
infect
present
twenti
compound
avail
treatment
hiv
infect
compound
fall
categori
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
didanosin
zalcitabin
stavudin
lamivudin
abacavir
emtricitabin
ii
nucleotid
revers
transcriptas
inhibitor
ntrti
tenofovir
disoproxil
fumar
iii
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
delavirdin
efavirenz
iv
proteas
inhibitor
pi
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
combin
ratio
ritonavir
atazanavir
fosamprenavir
tipranavir
darunavir
v
fusion
inhibitor
fi
enfuvirtid
sever
compound
also
avail
fix
dose
combin
zidovudin
lamivudin
lamivudin
abacavir
emtricitabin
tenofovir
disoproxil
fumar
tripledrug
fix
dose
combin
contain
efavirenz
emtricitabin
tenofovir
disoproxil
fumar
recent
launch
also
prodrug
benzophenon
gw
recent
progress
phase
ii
clinic
studi
proteas
inhibitor
brecanavir
gw
progress
phase
iiiii
clinic
trial
although
brecanavir
engend
vitro
drug
resist
develop
coadministr
brecanavir
mg
ritonavir
mg
significantli
increas
plasma
brecanavir
level
achiev
drug
concentr
predict
inhibit
proteas
inhibitorresist
hiv
mutant
pharmacokinet
boost
subtherapeut
dose
ritonavir
becom
standard
procedur
enhanc
system
drug
exposur
varieti
hiv
proteas
inhibitor
yet
compound
preclin
develop
andor
may
soon
proceed
clinic
phase
iii
clinic
studi
hiv
receptor
downmodul
cyclotriazadisulfonamid
cada
hiv
envelopebind
protein
cyanovirinn
topic
microbicid
antagonist
structur
relat
antagonist
deriv
bicyclam
current
pursu
phase
iiiii
clinic
trial
combin
granulocyt
colonystimul
factor
gcsf
mobil
autolog
hematopoiet
progen
itor
cell
antagonist
structur
relat
prove
highli
potent
oral
bioavail
inhibitor
strain
act
synergisti
calli
antiretrovir
anoth
oral
bioavail
inhibitor
hiv
infect
noteworthi
among
new
nrti
prodrug
nrti
dideoxyguanosin
thymin
dioxolan
dot
anoth
nrti
favor
oral
bioavailab
uniqu
drug
resist
profil
differ
nrti
newli
synthes
phosphon
analogu
includ
ntrti
propyl
adenin
hpmpa
report
inhibit
replic
vitro
nanomolar
concentr
among
nnrti
pursu
antihiv
potenti
thiocarboxanilid
dapivirin
topic
microbicid
rilpivirin
one
potent
antihiv
agent
ever
describ
novel
benzophenon
nnrti
activ
nm
rt
mutant
associ
clinic
resist
efavirenz
nevirapin
respect
alkenyldiarylmethan
adam
metabol
labil
methylest
moieti
replac
isoxazolon
isoxazol
oxazolon
cyano
substitu
polymeras
activ
revers
transcriptas
rt
entir
depend
heterodimer
structur
enzym
rt
dimer
therefor
repres
molecular
target
develop
new
hiv
inhibitor
point
attack
biso
dioxid
thymin
tsaot
deriv
class
compound
origin
categor
nnrti
number
compound
among
target
integras
novel
integras
inhibitor
deriv
quinolon
antibiot
phase
iii
clinic
studi
undertaken
prototyp
class
compound
compound
show
ec
nm
acut
infect
assay
effect
log
reduct
viral
load
shortterm
trial
shortterm
monotherapi
trial
hiv
integras
similarli
indolyl
aryl
sulfon
may
serv
platform
design
new
nnrti
effect
variant
recent
diketo
acid
bear
nucleobas
scaffold
iti
index
cell
cultur
meanwhil
hiv
vectorbas
singlecycl
assay
develop
facilit
evalu
potenti
hiv
integras
inhibitor
among
pi
novel
proteas
inhibitor
describ
design
specif
interact
backbon
hiv
proteas
activ
site
combat
drug
resist
among
triterpen
betulin
acid
deriv
new
potent
antihiv
agent
report
demonstr
better
antivir
profil
prototyp
compound
addit
aforement
cyanovirinn
thiocarboxanilid
dapivirin
compound
could
develop
topic
ie
vagin
microbicid
name
aglycon
glycopeptid
antibiot
vancomycin
teicoplanin
eremomycin
specif
interact
glycoprotein
also
plant
lectin
ie
galanthu
nivali
agglutinin
gna
hippeastrum
hybrid
agglutinin
hha
repres
potenti
candid
anti
hiv
microbicid
show
mark
stabil
rel
low
ph
high
temperatur
prolong
time
period
directli
interact
viral
envelop
prevent
entri
hiv
target
cell
upon
prolong
exposur
hiv
cell
cultur
hha
gna
viru
acquir
resist
mutat
glycoprotein
predominantli
locat
nglycosyl
asparagin
site
cyanovirinn
plant
lectin
gna
hha
term
carbohydratebind
agent
cba
due
carbohydratebind
properti
interact
viral
envelop
glycoprotein
therebi
prevent
hiv
entri
process
recent
nonpeptid
benzon
aphtacen
quinon
antibiot
pradimicin
describ
lowmolecularweight
cba
block
hiv
entri
specif
interact
mannos
moieti
avenu
explor
combin
differ
microbicid
nnrti
thiocarboxanilid
cellulos
acet
cap
viral
entri
inhibitor
exhibit
synergist
complementari
effect
fection
addit
shortag
sulfat
sulfon
polym
start
suramin
first
polysulfon
ever
shown
activ
hiv
could
consid
topic
antihiv
microbicid
rna
interfer
rnai
may
consid
new
power
tool
intracellular
immun
infect
demonstr
shortterm
assay
replic
inhibit
sirna
direct
viral
target
ie
rev
cellular
target
ie
viral
target
sirna
target
conserv
gag
pol
int
vpu
region
tat
rev
nef
shown
inhibit
viru
product
although
target
singl
sequenc
sirna
result
strong
inhibit
viral
replic
like
follow
escap
mutat
viral
variant
therefor
antivir
approach
involv
rnai
use
combin
fashion
prevent
emerg
resist
virus
furthermor
worth
investig
whether
rnai
har
use
microbicid
describ
sirnabas
microbicid
shown
protect
mice
lethal
fection
extens
result
design
hiv
microbicid
would
also
requir
demonstr
silenc
resid
tissu
macrophag
dendrit
cell
cell
consid
requir
combin
sirna
target
multipl
viral
gene
cover
viral
sequenc
divers
prevent
potenti
escap
mutat
develop
effect
sirnabas
hiv
microbicid
may
seem
challeng
task
forti
compound
regist
antivir
drug
least
half
use
treat
hiv
infect
even
greater
number
compound
clinic
preclin
develop
mani
target
hiv
virus
taken
togeth
impli
hiv
sinc
advent
remain
main
stay
process
hiv
potenti
virus
sar
coronaviru
rsv
antivir
agent
may
also
exert
antivir
effect
interact
cellular
target
imp
dehydrogenas
ribavirin
sah
hydrolas
latter
enzym
essenti
viral
rna
synthesi
suppli
gtp
viral
mrna
matur
cap
respect
final
interferon
gener
provid
pegyl
form
